BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that its management will present a company overview at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1, 2010, at 11:30 a.m. EST. The presentation will be webcast live and available for replay from Micromet's website, www.micromet.com, under the "Investors and Media" section.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
CONTACT:
Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications
240-235-0246
[email protected]
KEYWORDS: United States North America Maryland
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical General Health
MEDIA: